CN1110499C - 螺一奎宁环衍生物,它们的制备和用途 - Google Patents

螺一奎宁环衍生物,它们的制备和用途 Download PDF

Info

Publication number
CN1110499C
CN1110499C CN98805414A CN98805414A CN1110499C CN 1110499 C CN1110499 C CN 1110499C CN 98805414 A CN98805414 A CN 98805414A CN 98805414 A CN98805414 A CN 98805414A CN 1110499 C CN1110499 C CN 1110499C
Authority
CN
China
Prior art keywords
disease
imbalance
nicotine
symptom
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN98805414A
Other languages
English (en)
Chinese (zh)
Other versions
CN1257506A (zh
Inventor
D·彼得斯
G·M·奥尔森
S·F·尼尔森
E·Φ·尼尔森
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of CN1257506A publication Critical patent/CN1257506A/zh
Application granted granted Critical
Publication of CN1110499C publication Critical patent/CN1110499C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
    • C07D491/20—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Anesthesiology (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN98805414A 1997-05-30 1998-05-29 螺一奎宁环衍生物,它们的制备和用途 Expired - Fee Related CN1110499C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK0626/1997 1997-05-30
DK62697 1997-05-30

Publications (2)

Publication Number Publication Date
CN1257506A CN1257506A (zh) 2000-06-21
CN1110499C true CN1110499C (zh) 2003-06-04

Family

ID=8095721

Family Applications (1)

Application Number Title Priority Date Filing Date
CN98805414A Expired - Fee Related CN1110499C (zh) 1997-05-30 1998-05-29 螺一奎宁环衍生物,它们的制备和用途

Country Status (11)

Country Link
US (1) US6352995B1 (enExample)
EP (1) EP0984970B1 (enExample)
JP (1) JP2002500652A (enExample)
CN (1) CN1110499C (enExample)
AT (1) ATE254618T1 (enExample)
AU (1) AU744368B2 (enExample)
CA (1) CA2289578A1 (enExample)
DE (1) DE69819891T2 (enExample)
NZ (1) NZ500643A (enExample)
WO (1) WO1998054189A1 (enExample)
ZA (1) ZA984637B (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2790474B1 (fr) * 1999-03-05 2001-04-06 Synthelabo Derives de pyridopyranoazepines, leur preparation et leur application en therapeutique
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
WO2002015662A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists
JP2004506734A (ja) * 2000-08-21 2004-03-04 ファルマシア・アンド・アップジョン・カンパニー 疾患治療用のキヌクリド置換ヘテロアリール部分
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6569865B2 (en) 2001-06-01 2003-05-27 Astrazeneca Ab Spiro 1-azabicyclo[2.2.2]octane-3,2′(3′h)-furo[2,3-b]pyridine
EP1397366B1 (en) * 2001-06-01 2007-02-07 AstraZeneca AB Novel ligand for nicotinic acetylcholine receptors useful in therapy
US6919359B2 (en) 2001-11-08 2005-07-19 Pfizer Inc Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
JP2005537297A (ja) 2002-08-01 2005-12-08 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー アルファ−７ｎａｃｈｒ活性を有する１ｈ−ピラゾールおよび１ｈ−ピロール−アザビシクロ化合物
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
US9119846B2 (en) 2003-04-29 2015-09-01 Neurim Pharmaceuticals (1991) Ltd. Method and composition for enhancing cognition in alzheimer's patients
IL155666A (en) * 2003-04-29 2013-12-31 Neurim Pharma 1991 Insomnia treatment
US20050137217A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji Spirocyclic quinuclidinic ether derivatives
US7045530B2 (en) 2003-12-22 2006-05-16 Abbott Laboratories Spirocyclic quinuclidinic ether derivatives
PE20060437A1 (es) 2004-06-18 2006-06-08 Novartis Ag COMPUESTOS AZA-BICICLONONANOS COMO LIGANDOS COLINERGICOS DE nAChR
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
CA2580329C (en) 2004-09-13 2015-01-06 Chrono Therapeutics Inc. Biosynchronous transdermal drug delivery
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
EP1977746B8 (en) 2007-04-02 2014-09-24 Parkinson's Institute Methods and compositions for reduction of side effects of therapeutic treatments
CA2974324A1 (en) 2015-01-28 2016-08-04 Zita S. Netzel Drug delivery methods and systems
EP3565617A1 (en) 2017-01-06 2019-11-13 Chrono Therapeutics Inc. Transdermal drug delivery devices and methods
US11596779B2 (en) 2018-05-29 2023-03-07 Morningside Venture Investments Limited Drug delivery methods and systems
CA3119992A1 (en) 2018-11-16 2020-05-22 Morningside Venture Investments Limited Thermally regulated transdermal drug delivery system

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL48452A (en) 1975-11-11 1979-07-25 Purdue Frederick Co Spiro (1,3-dioxolane-4,3') quinuclidines,their preparationand pharmaceutical compositions comprising them
IL87234A (en) 1987-08-13 1992-02-16 Israel Inst Biolog Res Optical isomers of 2-methylspiro(1,3-oxathiolane-5,3')quinuclidine,their preparation and pharmaceutical compositions containing them
DE3853758T2 (de) 1987-10-05 1995-09-07 Yamanouchi Pharma Co Ltd Heterozyklische Spiroverbindungen und ihre Herstellung.
US4876260A (en) 1987-10-28 1989-10-24 State Of Israel, Israel Institute Of Biological Research Oxathiolanes
GB8816299D0 (en) * 1988-07-08 1988-08-10 Merck Sharp & Dohme Therapeutic agents
US5534520A (en) 1990-04-10 1996-07-09 Fisher; Abraham Spiro compounds containing five-membered rings
US5803081A (en) * 1996-06-28 1998-09-08 Regent Court Technologies Tobacco and related products
AR013184A1 (es) 1997-07-18 2000-12-13 Astrazeneca Ab Aminas heterociclicas espiroazobiciclicas, composicion farmaceutica, uso de dichas aminas para preparar medicamentos y metodo de tratamiento o profilaxis

Also Published As

Publication number Publication date
CN1257506A (zh) 2000-06-21
ATE254618T1 (de) 2003-12-15
AU744368B2 (en) 2002-02-21
CA2289578A1 (en) 1998-12-03
EP0984970B1 (en) 2003-11-19
US6352995B1 (en) 2002-03-05
DE69819891T2 (de) 2004-08-26
AU7426398A (en) 1998-12-30
DE69819891D1 (de) 2003-12-24
EP0984970A1 (en) 2000-03-15
WO1998054189A1 (en) 1998-12-03
ZA984637B (en) 1998-12-21
NZ500643A (en) 2001-12-21
JP2002500652A (ja) 2002-01-08

Similar Documents

Publication Publication Date Title
CN1110499C (zh) 螺一奎宁环衍生物,它们的制备和用途
CN1257499A (zh) 在尼古丁ach受体上作为胆碱能配体的8－氮杂双环(3,2,1)辛－2－烯以及辛烷衍生物
CN1060775C (zh) 用作神经递质重摄取抑制剂的稠合莨菪烷衍生物
CN1083840C (zh) 8－氮杂双环[3.2.1]辛－2－烯衍生物,它们的制备和用途
ES2338656T3 (es) Uso farmaceutico de 1,2,4-triazoles fusionados.
JP5894574B2 (ja) 有機化合物
KR101724161B1 (ko) 세포내 칼슘을 조절하는 화합물
AU692788B2 (en) Piperazine compounds used in therapy
JP4677518B2 (ja) 新規ピペリジニルアミノ−チエノ［２，３−ｄ］ピリミジン化合物
JP2008500390A (ja) 疾患治療薬としての選択的セロトニン受容体逆作動薬
CN1347414A (zh) 对多巴胺d3受体具有亲和力的三唑化合物
JP2011516599A (ja) ニコチン性アセチルコリン受容体サブタイプα７のモジュレーターとしてのインドール類
JP4897683B2 (ja) チエノピリジノン化合物及び治療方法
JP6977024B2 (ja) ５−ｈｔ２ｃ受容体アゴニストおよび組成物ならびに使用方法
TW200400037A (en) 5Ht2c receptor modulators
CN101090895A (zh) 芳基磺酰胺调节剂
TW201835081A (zh) 具有體抑素受體促效活性之化合物及其醫藥用途
JP2001501203A (ja) スピロアザシクロ誘導体、該誘導体の製造およびタキキニン拮抗薬としての該誘導体の使用
TW201028395A (en) Biologically active amides
CN1173972C (zh) 氮杂环醚衍生物及其作为烟碱乙酰胆碱受体调节剂的应用
JP2008524213A (ja) 新規なピラゾール誘導体及びニコチン性アセチルコリン受容体のモジュレーターとしてのそれらの使用
TW200922584A (en) Organic compounds
JP2005522456A (ja) Ｃｎｓ関連障害治療のためのアザビシクロ置換ベンゾイルアミドおよびチオアミド
JP2011201777A (ja) 光学活性なヘテロシクリデン−ｎ−アリールアセトアミド誘導体
CN1257485A (zh) 氮杂环辛烷和庚烷衍生物、其制备方法和治疗用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee